UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 26

Sortiert nach

Mesenchymal stem cells in cancer : Tumor-associated fibroblasts and cell-based delivery vehicles

International journal of hematology, 2007-07, Vol.86 (1), p.8-16

2007

Volltextzugriff (PDF)

Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents

JNCI : Journal of the National Cancer Institute, 2004-11, Vol.96 (21), p.1593-1603

2004

Volltextzugriff (PDF)

Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas

Cancer research (Chicago, Ill.), 2005-04, Vol.65 (8), p.3307-3318

2005

Volltextzugriff (PDF)

First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.8502-8502

2023

Volltextzugriff (PDF)

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

Future oncology (London, England), 2022-08, Vol.18 (24), p.2639-2649

2022

Volltextzugriff (PDF)

A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS8588-TPS8588

2021

Volltextzugriff (PDF)

CTIM-30. A PHASE 1B, OPEN-LABEL, DOSE-ESCALATION TRIAL OF THE DELTA-LIKE LIGAND 3 (DLL3)/CD3 IGG-LIKE T CELL ENGAGER, BI 764532, IN PATIENTS WITH DLL3-POSITIVE GLIOMA

Neuro-oncology (Charlottesville, Va.), 2023-11, Vol.25 (Supplement_5), p.v69-v69

2023

Volltextzugriff (PDF)

RESPONSE: Re: Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents

JNCI : Journal of the National Cancer Institute, 2005-04, Vol.97 (7), p.541-542

2005

Volltextzugriff (PDF)

Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis

BMC cancer, 2014-07, Vol.14 (1), p.510-510, Article 510

2014

Volltextzugriff (PDF)

Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors

Cancer research (Chicago, Ill.), 2002-07, Vol.62 (13), p.3603-3608

2002

Volltextzugriff (PDF)

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study

Investigational new drugs, 2013-10, Vol.31 (5), p.1283-1293

2013

Volltextzugriff (PDF)

Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment

Clinical colorectal cancer, 2016-03, Vol.15 (1), p.91-94.e1

2016

Volltextzugriff (PDF)

LUME-Colon 1: a randomized phase III study of nintedanib vs placebo in patients with advanced colorectal cancer

Annals of oncology, 2015-11, Vol.26, p.vii130

2015

Volltextzugriff (PDF)

Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer

Cytotherapy (Oxford, England), 2013, Vol.15 (1), p.20-32.e2

2013

Volltextzugriff (PDF)

Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells

Cancer gene therapy, 2010-04, Vol.17 (4), p.289-297

2010

Volltextzugriff (PDF)

Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.4506-4506

2013

Volltextzugriff (PDF)

Open-label, phase I/randomized, phase II trial of the triple angiokinase inhibitor, nintedanib, versus sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS4160-TPS4160

2013

Volltextzugriff (PDF)

Effects of nintedanib (BIBF 1120) on QTc interval in previously untreated patients with renal cell cancer (RCC): Results from an open-label, phase II study

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e15037-e15037

2012

Volltextzugriff (PDF)

for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents

JNCI : Journal of the National Cancer Institute, 2005-04, Vol.97 (7), p.541-542

2005

Volltextzugriff (PDF)

447. Mesenchymal Stem Cells as Delivery Systems for Cancer Therapy: Evaluation of Tropism and Efficacy

Molecular therapy, 2005-05, Vol.11 (S1), p.S173-S173

2005

Volltextzugriff (PDF)

Mesenchymal Stem Cells Selectively Engraft into Tumor Stroma and Produce Potent Antitumor Proteins In Situ

Blood, 2006-11, Vol.108 (11), p.352-352

2006

Volltextzugriff (PDF)

Mesenchymal stem cells (MSC) as carriers of biologically active molecules in cancer and leukemia therapy

European journal of cancer (1990), 2001-09, Vol.37, p.S81-S81

2001

Volltextzugriff (PDF)

Mesenchymal Stem Cells as Vehicles for Genetic Targeting of Tumors

Stem Cell Transplantation, 2006, p.157-175

2006

Volltextzugriff (PDF)

Tribological Properties of 3D Printed Materials in Total Knee Endoprosthesis

Manufacturing Technology, 2024-04, Vol.24 (2), p.294-306

2024

Volltextzugriff (PDF)

1 – 25 von 26

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(25)
Buchkapitel
(1)

Sprache

Englisch
(26)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mesenchymal stem cells in cancer : Tumor-associated fibroblasts and cell-based delivery vehicles

Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents

Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas

First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC)

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3

CTIM-30. A PHASE 1B, OPEN-LABEL, DOSE-ESCALATION TRIAL OF THE DELTA-LIKE LIGAND 3 (DLL3)/CD3 IGG-LIKE T CELL ENGAGER, BI 764532, IN PATIENTS WITH DLL3-POSITIVE GLIOMA

RESPONSE: Re: Mesenchymal Stem Cells: Potential Precursors for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents

Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis

Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study

Rationale and Design for the LUME-Colon 1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Nintedanib Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients With Advanced Colorectal Cancer Refractory to Standard Treatment

LUME-Colon 1: a randomized phase III study of nintedanib vs placebo in patients with advanced colorectal cancer

Tumor stroma engraftment of gene-modified mesenchymal stem cells as anti-tumor therapy against ovarian cancer

Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells

Nintedanib (N) plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies: Health-related quality of life (HRQoL) results of the Phase III LUME-Colon 1 study

Phase II efficacy and safety study of nintedanib versus sunitinib in previously untreated renal cell carcinoma (RCC) patients

Open-label, phase I/randomized, phase II trial of the triple angiokinase inhibitor, nintedanib, versus sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC)

Effects of nintedanib (BIBF 1120) on QTc interval in previously untreated patients with renal cell cancer (RCC): Results from an open-label, phase II study

for Tumor Stroma and Targeted-Delivery Vehicles for Anticancer Agents

447. Mesenchymal Stem Cells as Delivery Systems for Cancer Therapy: Evaluation of Tropism and Efficacy

Mesenchymal Stem Cells Selectively Engraft into Tumor Stroma and Produce Potent Antitumor Proteins In Situ

Mesenchymal stem cells (MSC) as carriers of biologically active molecules in cancer and leukemia therapy

Mesenchymal Stem Cells as Vehicles for Genetic Targeting of Tumors

Tribological Properties of 3D Printed Materials in Total Knee Endoprosthesis

Suchergebnisse filtern